Nuwellis

NUWE

Market cap $2.82M

Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid management in pediatric heart failure Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid management in pediatric heart failure

MINNEAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent covering its novel dual lumen midline catheter technology designed for use in ultrafiltration therapies. This next-generation catheter incorporates advanced design elements to optimize blood flow dynamics during therapy.

Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530 Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530

MINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex SmartFlow® ultrafiltration platform. The update is designed to improve usability, streamline clinical workflow, and enhance overall user experience.

MINNEAPOLIS, April 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the return of three former team members: Liby Cielo, Principal Account Manager; Meredith Stein, Senior Clinical Education Specialist; and Scott Campbell, Area Vice President, Sales. The addition of these returning team members reflects Nuwellis' continued focus on strengthening its commercial and clinical capabilities and supporting hospitals treating patients with complex cardiorenal conditions.

MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services.

Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region

Pediatric footprint expands to 47 centers nationwide, including six of the nation's top 10 children's hospitals Pediatric footprint expands to 47 centers nationwide, including six of the nation's top 10 children's hospitals

MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd.

Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript